Clinical trials: Choroid Neovascularization Secondary to Degenerative Myopia
Choroidal Neovascularization, Myopia, Degenerative
Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
The objectives of this study are to evaluate the safety and efficacy of 3 dose groups (27, 36 and 45 mg/m2) of Combretastatin A-4 Phosphate for the treatment of subfoveal choroidal neovascularization in subjects with pathologic…
- Trial name
- NCT01423149
- Testing
- Combretastatin A-4 Phosphate
- Volunteers
- 23 people
- Sponsor
- Mateon Therapeutics
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease…
- Trial name
- OLIMPIC (NCT02034006)
- Testing
- Ranibizumab
- Where
- 31 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Myopia
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Anti-VEGF therapy has been proven efficacious for the wet (neovascular) form of macular degeneration and may be beneficial for the treatment of choroidal neovascularization (CNV) due to other causes.
- Conditions
- Choroidal Neovascularization, Myopia, Punctate Inner Choroidopathy (PIC), Multifocal Choroiditis
- Trial name
- CNV (NCT01256580)
- Testing
- Bevacizumab (Avastin; Genentech, Inc.), Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
- Sponsor
- Massachusetts Eye and Ear Infirmary
Choroid Neovascularization Secondary to Degenerative Myopia
A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV
This study is design to evaluate the effect of conbercept therapy on visual acuity and anatomic outcomes compared to sham injection and durability of response observed in subjects with choroid neovascularization secondary to…
- Trial name
- SHINY (NCT01809223)
- Testing
- conbercept, Fixed, conbercept, PRN
- Where
- 13 sites in China
- Volunteers
- 176 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Choroidal Neovascularization, Degenerative Myopia
Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study is to see if the drug bevacizumab is safe and effective to use for people with choroidal neovascularization (CNV).
- Conditions
- Choroidal Neovascularization, Degenerative Myopia, Pathological Myopia
- Trial name
- NCT00407719
- Testing
- Bevacizumab
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Choroidal Neovascularisation
Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen
This study is designed to provide efficacy and safety data in patients with choroidal neovascularisation (CNV) secondary to myopia using an individualized as-needed (PRN) dosing schedule.
- Trial name
- REPAIR (NCT01037348)
- Testing
- ranibizumab 0.5mg
- Where
- 12 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Novartis
Pathological Myopia
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- NCT01217944
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 74 sites in Austria, Canada and 18 more
- Volunteers
- 277 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema
A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar).
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema, Myopic Choroidal Neovascularization
- Trial name
- NCT07550504
- Testing
- SB11 PFS
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Retinal Disease
Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
The study aims to collect data on the safety and use of intravitreal aflibercept injections into the eye for the treatment of eye disorders that cause blurred vision or a blind spot due to abnormal or blocked blood vessels.
- Trial name
- MAIA (NCT04137120)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- Mexico
- Volunteers
- 73 people
- Sponsor
- Bayer
Myopia, Pathological
VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to choroidal neovascularization secondary to pathologic myopia. This will be a placebo-controlled trial.
- Trial name
- Myrror (NCT01249664)
- Testing
- VEGF Trap-Eye (BAY86-5321), No Drug
- Where
- 20 sites in Hong Kong, Japan and 3 more
- Volunteers
- 122 people
- Sponsor
- Bayer